GlassScriptPhysician profile
Ashraf G Andrawis
NPI 1568445666
$6,961.96
in general payments reported to CMS, 2019-2025
49 companies · $379 in 2025
The $379 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $1,012 · 2021: $2,148 · 2022: $1,270 · 2023: $694 · 2024: $669 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,708 · Education: $33.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,708.15 |
| Education | $33.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,480.29 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Collegium Pharmaceutical, INC. | $913.29 | 2019-2025 | Xtampza, Belbuca |
| Allergan, INC. | $833.64 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $690.77 | 2019-2024 | Relistor |
| Merz North America, INC. | $335.66 | 2021 | |
| Amgen INC. | $316.50 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $229.76 | 2021 | |
| Pfizer INC. | $195.49 | 2020-2025 | |
| Daiichi Sankyo INC. | $155.04 | 2019 | |
| Indivior INC. | $131.05 | 2019-2025 | Sublocade |
| Protega Pharmaceutials INC | $128.11 | 2022-2025 | Roxybond |
| Acelrx Pharmaceuticals, INC. | $127.16 | 2019-2020 | |
| Pacira Therapeutics, INC. | $120.68 | 2019-2021 | |
| Orexo US, INC. | $101.34 | 2019-2023 | Zubsolv |
| Almatica Pharma LLC | $95.36 | 2021-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Andrawis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.